Skip to main content

Table 4 Clinical and demographic characteristics of the patients

From: Expression and 7-day time course of circulating microRNAs in septic patients treated with nephrotoxic antibiotic agents

 

Vancomycin group

Gentamicin group

oATB group

P

N (%)

7 (15)

20 (43)

19 (41)

 

Age (years)

65 (47–76)

59 (47–72)

65 (63–68)

0.785

Male n (%)

4 (57)

13 (65)

13 (68)

0.866

BMI (kg/m2)

26.2 (23.3–27.8)

28.4 (24.0–32.5)

26.3 (24.7–30.9)

0.620

SOFA score (%)

10 (7–14) + 1

QuickSOFA

8 (5–12)

7 (3–10)

0.406

AKI stage at baseline/end of study, all n (%)

 1

1 (14) / 1 (14)

5 (25) / 3 (15)

4 (21) / 3 (16)

0.836/0.995

 2

N

5 (25) / 1 (20)

6 (32) / 0

0.243/0.515

 3

2 (29) / 2 (29)

2 (10) /5 (5)

6 (32) / 9 (47)

0.236/0.318

No AKI

4 (57) / 4 (57)

8 (40) / 11 (55)

3 (15) / 7 (37)

0.088/0.455

RRT initiation, n (%)

2 (2)

5 (25)

7 (37)

0.719

Use of vasopressors, n (%)

6 (86)

15 (75)

11 (58)

0.307

Type of vasopressor, n (%)

 Norepinephrine

6 (100)

14 (93)

8 (73)

0.172

 Dobutamine

N

N

1 (9)

0.484

 Dopamine

N

N

1 (9)

0.484

 Norepinephrine + Dobutamine

N

1 (7)

1 (9)

0.416

Dose of vasopressors (μg/kg/min)

 Norepinephrine

0.18 (0.14–0.23)

0.21 (0.17–0.29)

0.32 (0.22–0.45)

0.104

 Dobutamine

N

N

1.79 (1.19–2.38)

0.333

 Dopamine

N

N

24.41 (19.41–29.41)

0.333

 Norepinephrine / Dobutamine

N / N

0.14 (0.001–0.28) / 1.04 (0.69–1.39)

0.24 (0.002–0.48) / 11.63 (0.16–23.10)

0.467/0.600

Duration of vasopressors therapy (days)

10 (6–12)

6 (2–9)

6 (3–13)

0.256

ICU hospitalized patients, n (%)

6 (86)

18 (90)

15 (79)

0.629

ICU length of stay (days)

18 (11–38)

13 (9–23)

12 (10–22)

0.585

Intermediate care hospitalized patients, n (%)

1 (14)

2 (10)

4 (21)

0.629

Intermediate care length of stay (days)

12

9 (8–10)

16 (10–24)

0.438

Total length of hospitalization (days)

31 (12–52)

25 (15–35)

17 (12–24)

0.162

Diagnoses, all n (%)

    

Urogenital infection

2 (29)

4 (20)

5 (26)

0.856

Pneumonia

    

 - Nosocomial

1 (14)

2 (10)

2 (11)

0.950

 - Community acquired

N

N

2 (11)

0.226

Sepsis in severe trauma

1 (14)

4 (20)

N

0.127

Peritonitis

1 (14)

6 (30)

1 (5)

0.122

Mediastinitis

1 (14)

1 (5)

N

0.280

Liver abscess

1 (14)

N

N

0.058

Acute cholecystitis

N

N

1 (5)

0.484

Acute pancreatitis

N

N

1 (5)

0.484

Infectious gastroenteritis

N

N

1 (5)

0.484

Abscess or phlegmon

N

2 (10)

3 (16)

0.511

Erysipelas

N

N

1 (5)

0.484

Sepsis of unknown origin

N

1 (5)

2 (11)

0.587

Clinical outcome survived/died, n (%)

6 (86) / 1 (14)

18 (90) / 2 (10)

15 (79) / 4 (21)

0.629

  1. Abbreviations: AKI acute kidney injury, BMI body mass index, ICU intensive care unit, N none, oATB group other ATB group, RRT renal replacement therapy, SOFA Sequential Organ Failure Assessment score
  2. Quantitative variables are presented as medians and interquartile ranges. Qualitative variables are presented as counts and percentages. P values are from Kruskal–Wallis tests for quantitative variables and Pearson’s χ2 tests for qualitative variables